Zenas BioPharma (NASDAQ:ZBIO) Rating Increased to Hold at Wall Street Zen

Key Points

• Zenas BioPharma (NASDAQ:ZBIO) has been upgraded from a "sell" rating to a "hold" rating by analysts at Wall Street Zen.
• Despite a recent quarterly earnings report showing a loss of ($1.25) per share, three analysts maintain a "buy" rating for the stock with an average price target of $36.67.
• The company has a market cap of $863.68 million and observed stock performance with a 1-year low of $5.83 and a high of $26.25.

Wall Street Zen upgraded shares of Zenas BioPharma (NASDAQ:ZBIO - Free Report) from a sell rating to a hold rating in a research report report published on Friday morning.

Several other brokerages also recently weighed in on ZBIO. Wedbush restated an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Zenas BioPharma in a research report on Friday, May 16th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $36.67.

Zenas BioPharma Price Performance

Shares of NASDAQ:ZBIO traded up $0.38 during trading on Friday, reaching $20.17. 118,479 shares of the company traded hands, compared to its average volume of 223,124. The business's 50 day moving average price is $15.62. The company has a market capitalization of $849.36 million and a price-to-earnings ratio of -5.68. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $26.25.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund acquired a new position in Zenas BioPharma in the 1st quarter worth about $49,000. PNC Financial Services Group Inc. increased its stake in shares of Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares during the period. Sei Investments Co. bought a new position in shares of Zenas BioPharma during the second quarter worth about $118,000. Intech Investment Management LLC raised its position in shares of Zenas BioPharma by 13.9% during the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company's stock worth $128,000 after acquiring an additional 1,607 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Zenas BioPharma by 32.3% during the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after acquiring an additional 3,412 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.